european medicines agency glp-1 vision loss recommendation november 2025 Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January Meeting highlights from the Pharmacovigilance

Since their introduction in 2005, GLP-1 medications like Ozempic and Wegovy have transformed diabetes treatment and weight management

WHO GLP-1 Treatments: The World Health Organization has issued new guidelines endorsing GLP-1 agonists as essential treatments for obesity, highlighting the urgent need for action against the rising global obesity epidemic affecting over one billion people and posing serious health risks.

Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are among the leading causes of disability worldwide and are frequently associated with treatment resistance, functional impairment, and high comorbidity with ...

A new study is warning that the packaging of marijuana edibles is being made to look like name brand popular snacks and candies and could pose a risk to young children

As noted by Novo Nordisks CEO, it is both surprising but also positive for the commercial development of the obesity market that large populations in both the US and Europe have shown willingness to pay for private prescriptions of Wegovy and other agents out of pocket

They are breaking out and shaking up the entire healthcare scene